CD44 and cancer: For example, a phase 1 clinical trial with 12 patients indicated that HA‐irinotecan is safe, well‐tolerated, and does not compromise the anticancer activity of irinotecan.[339] Another phase 2 trial with 41 patients highlighted the advantages of HA nanoformulations for targeting CD44 isoforms created by variable exon splicing and post‐transcriptional modifications in gene expression.[340] Pramanik et al demonstrated the promising cancer therapeutic potential of HA‐functionalized cubosomes, liquid crystalline lipid NPs.